ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,673.00
3.00 (0.18%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.00 0.18% 1,673.00 1,674.00 1,675.00 1,679.50 1,658.50 1,661.50 7,034,492 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.99 68.96B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,670p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £68.96 billion. Gsk has a price to earnings ratio (PE ratio) of 13.99.

Gsk Share Discussion Threads

Showing 13826 to 13849 of 33125 messages
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older
DateSubjectAuthorDiscuss
17/2/2017
07:38
Isn't it ex div today?
ny boy
16/2/2017
15:40
flying today.

Next stop £17, or maybe a pause at 16.50?

tim 3
16/2/2017
12:18
Breaking higher
ny boy
16/2/2017
11:46
NY Boy - Seems to be doing well, I'm happy with the ViiV statement, good start for new CEO, but things can change haha.
losos
16/2/2017
08:17
Broken through 1592p resistance, closes above this level, suggest a crack at next resistance level 1715p this quarter.
ny boy
16/2/2017
08:05
Breakout coming?
ny boy
15/2/2017
13:20
Beaufort Securities note:

Our view: Positive progress for ViiV Healthcare. The announcement follows positive headline results announced on 20 December 2016. The details study results are being presented at the annual Conference on Retroviruses and Opportunistic Infections in Seattle.

Although share price moved marginally adverse yesterday, possibly due to investors wished to see Virologic suppression rates for two-drug regimen superior against the CAR arms, the result itself came no surprise since the December.

The Group said for over 20 years, the industry believed that three or more drugs were required to maintain virologic suppression, but the study of dolutegravir and rilpivirine provide data showing suppression may be maintained with a two-drug regimen. The studies are ongoing for 148 weeks, and the Group is planning regulatory submissions for this two-drug regimen as a single tablet during 2017.

GSK was entitled to approximately 80% of the core earnings of ViiV Healthcare for 2016 (allocation of the overall earnings of ViiV Healthcare to each shareholder will change based on the relative performance of the products), meaning that, if progress continues along the same lines as in 2016, this should be slightly earnings enhancing for GSK going forward.

In light of the on-going developments, Beaufort maintain a Buy rating on GlaxoSmithKline with a target price of 1,750p per share.


proactiveinvestors.co.uk

philanderer
15/2/2017
11:34
No, XD Thursday week.
essentialinvestor
15/2/2017
11:26
Will a special dividend be paid this year, in additional to the final dividend, as per the last two years ?
avidacre
15/2/2017
10:33
Would not like to be in my teens again, but would kill for those energy levels )
essentialinvestor
15/2/2017
09:10
I'm still in my teens..😀
ny boy
14/2/2017
13:58
lol!!, believe me I take quite a bit of medication so very unlikely
to make old bones, so 40's are the new 60's for me.

essentialinvestor
14/2/2017
13:44
Wish I were still middle aged ES :-)
sicker
14/2/2017
13:33
Nope, you are not, tend to be a middle aged cynic these days but AW can be proud
of his efforts in access to medicines for poorer countries, GSK do more
than about any other pharma company in this area.

essentialinvestor
14/2/2017
13:29
Pity more directors would not replicate Andrew Witty's gift of shares in the aid of science. (hope I'm not spouting rubbish :-))
sicker
14/2/2017
10:51
Yes, that's much needed.

(Today ViiV Healthcare announced detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment)

tradermichael
14/2/2017
10:39
Michael, Gilead announced some positive data on their new HIV compound
yesterday, it's Phase 11, so needs to clear the larger phase 111 hurdle before they file.

Would expect ViiV will file for approval asap on today's news.

essentialinvestor
14/2/2017
10:36
updated:

14th feb Liberum buy tp 1900p
14th feb Shore Cap hold -
13th feb Jefferies buy tp 1780p
10th feb Berenberg buy tp 1850p
10th feb JP Morgan neutral tp 1670p
10th feb Beaufort buy tp 1750p
10th feb Deutsche hold tp 1720p


8th feb ++++ Q4 results ++++

philanderer
14/2/2017
09:51
I'll be buying some more when the next dividend comes in ..... ;0)
tradermichael
14/2/2017
09:50
Just out of bed :-)


... good update

philanderer
14/2/2017
09:44
x div next week, 23 February ..... ;0)
tradermichael
14/2/2017
09:00
Must be going ex divi soon

Happy with my holding from 1510p

ny boy
14/2/2017
08:15
Added a few under 15.65, the news was not unexpected as mentioned.
essentialinvestor
14/2/2017
07:36
Great news - glad I've been topping up at the lows.
woodhawk
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older

Your Recent History

Delayed Upgrade Clock